Gapping up
In reaction to strong earnings/guidance:
- GSM +20.1%, MNK +15.3%, THC +13.3%, DDS +12.8%, VCEL +12.5%, SNHY +11.2%, HTZ +11%, ETSY +10.5%, HSII +7.8%, AZO +7.7%, SJM +6.9%, EVER +6.6%, TWOU +5.4%, MOS +5.3%, RCII +4.6%, SDRL +3.8%, SPNS +3.1%, CORT +2.8%, CRZO +2.2%, DISCA +2%, ATHM +1.7%, WP +1.7%, RRC +1.6%, APLE +1.6%, APTS +1.6%, TPH +1.5%, JBT +1.1%
Other news:
- APHA +5% (worldwide license agreement with Manna Molecular Science, producers of state-of-the-art cannabis transdermal patches) I +4.9% (initiated with Outperform at Evercore ISI)
- NIO +3.9% (continued strength)
- IOVA +2.6% (receives FDA Fast Track designation for LN-145 for the treatment of cervical cancer)
- NTR +1.7% (responds to speculation about potential corporate activity with Ruralco, confirms that its Landmark business is engaged in discussions with Ruralco regarding a potential transaction)
- MAT +1.4% (CEO bought ~71K shares worth ~$1 mln and CFO bought 20K shares worth ~$280K)
- ACB +0.8% (to acquire a 51% ownership interest in Gaia Pharm )
Analyst comments:
- KDMN +5.7% (upgraded to Buy from Neutral at Citigroup)
- AMH +3.1% (upgraded to Buy from Neutral at Mizuho)
- EXAS +3.1% (upgraded to Buy from Neutral at Goldman)
